Markets
English
PSTI
 

Trade Pluristem Therapeutics Inc. - PSTI CFD

1m
5m
15m
30m
1H
4H
1D
1W

Trader sentiment

% Buyers % Sellers
  • Long position overnight fee -0.0225%
    Margin $1,000.00
    Overnight feeCharges from borrowed part ($-0.90) -0.0225 %
  • Short position overnight fee -0.0219%
    Margin $1,000.00
    Overnight feeCharges from borrowed part ($-0.88) -0.0219 %
  • Overnight fee time 22:00 (UTC)
  • Min traded quantity 1
  • Currency USD
  • Margin 20%
  • Stock exchange United States of America
  • Trading hours (UTC)
    Mon - Fri: 14:30 - 21:00
  • Commission on trade 0%

0+

Traders

0+

Active clients monthly

$0+

Monthly investing volume

$0+

Withdrawn each month

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA''s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant''s patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Trade shares with leverage

Shares are available to trade with up to 5:1 leverage. Start trading with as little as $100 to control a position of $500

Shares CFDs

  • Trade 24/5 on a wide range of shares

  • Trading opportunities in both a rising and falling market

Profit and loss control

You can easily define Stops and Limits to request positions to close at a specified price.

Set up price alerts to be informed of big moves.

You might be interested in

Still looking for a broker you can trust?


Join the 300,000+ traders worldwide that chose to trade with Capital.com

1. Create your account

2. Make your first deposit

3. You’re all set. Start trading